Overview
- 4 inspections across 4 sites are on record.
- 3 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2025-03-27.
At a glance
Inspections
4
Sites
4
Observations
3
Career since
Nov 2016
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Eli Lilly & Company | 27 Mar 2025 | Human Drugs | |
| Nektar Therapeutics | 1 Feb 2019 | Human Drugs | |
| David Kudrow, M.D. | 8 Dec 2017 | Human Drugs | |
| Julio C. Castro-Gayol, M.D. | 18 Nov 2016 | Human Drugs |
Sites inspected
Eli Lilly & CompanyIndianapolis, United States1 insp.
Nektar TherapeuticsSan Francisco, United States1 insp.
David Kudrow, M.D.Santa Monica, United States1 insp.
Julio C. Castro-Gayol, M.D.Hialeah, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Full investigator report
Get the verbatim findings behind Cara L Alfaro's 3 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site